Outset Medical revenue falls 6% as shareholder lawsuits allege securities fraud

Filed May 7, 2026 · Period ending March 31, 2026 · Compared to 10-Q May 8, 2025 · ~2 min read

Key Changes

• high

  Two shareholder class actions filed in 2024 allege the company made false statements about Tablo products and FDA processes that misled investors about revenue growth prospects. Additional derivative suits filed through April 2025 claim breach of fiduciary duty by directors and officers.

  Risk Factors: Securities Litigation verify on EDGAR →
• high

  Q1 2026 revenue declined 6% year-over-year to $27.9 million, reversing prior year's 6% growth. Product revenue fell 13% with declines in both console and consumable sales, signaling weakening demand across the installed base.

  MD&A: Revenue Performance verify on EDGAR →
• high

  New risk disclosure warns that current administration efforts to cut federal healthcare agency budgets and staffing at FDA, HHS, and CMS could slow regulatory reviews, delay product approvals, and increase costs for future product modifications.

  Risk Factors: Regulatory Policy Changes verify on EDGAR →